Examples of using Cuscc in English and their translations into German
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Cases of cuSCC have been reported in patients treated with vemurafenib.
Patients with advanced BCC have an increased risk of developing cuSCC.
CuSCC was very commonly reported and was most commonly treated by local excision.
Therefore, all patients shouldbe monitored routinely while taking Odomzo, and cuSCC should be treated according to the standard of care.
In patients who develop cuSCC, it is recommended to continue the treatment without dose adjustment.
Older patients(≥ 65 years) may be more likely to experience adverse reactions,including cuSCC, decreased appetite, and cardiac disorders.
Cases of cuSCC can be managed with excision and do not require treatment modification.
Up to 1 in 10 people taking Tafinlar may develop a different type of skin cancercalled cutaneous squamous cell carcinoma cuSCC.
Cases of cuSCC have been reported in advanced BCC patients treated with Erivedge.
Taking the combination of Mekinist and dabrafenib may cause a different type of skin cancercalled cutaneous squamous cell carcinoma cuSCC.
The incidence of cuSCC in vemurafenib-treated patients across studies was approximately 20.
Therefore, all patients shouldbe monitored routinely while taking Erivedge, and cuSCC should be treated according to the standard of care.
CuSCC usually occurred early in the course of treatment with a median time to the first appearance of 7 to 8 weeks.
Dose modifications are not recommended for adversereactions of cutaneous squamous cell carcinoma(cuSCC) or new primary melanoma see dabrafenib SmPC for further details.
Cases of cuSCC(including keratoacanthoma) have been reported in patients treated with trametinib in combination with dabrafenib.
Ninety-six percent of patients on dabrafenib monotherapy in the integrated safety population andall patients on combination therapy in the Phase III studies who developed cuSCC continued on treatment without dose modification.
Of the patients who experienced cuSCC, approximately 33% experienced> 1 occurrence with median time between occurrences of 6 weeks.
Cases of cuSCC were typically managed with simple excision, and patients generally continued on treatment without dose modification see sections 4.2 and 4.4.
In the event the patientdevelops Cutaneous Squamous Cell Carcinoma(cuSCC), it is recommended to continue the treatment without modifying the dose of vemurafenib see sections 4.4 and 4.8.
In the Phase III study MEK115306, cuSCC occurred in 3%(6/209) of patients receiving trametinib in combination with dabrafenib and 10%(22/211) of patients receiving dabrafenib as a single agent.
In the Phase III study MEK116513, cuSCC occurred in 1%(5/350) of patients receiving trametinib in combination with dabrafenib and 18%(63/349) of patients receiving vemurafenib as a single agent.